Evogene
EVGN
18 hedge funds and large institutions have $79.8M invested in Evogene in 2014 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
6% more funds holding
Funds holding: 17 → 18 (+1)
3.16% less ownership
Funds ownership: 19.64% → 16.47% (-3.2%)
17% less capital invested
Capital invested by funds: $95.7M → $79.8M (-$15.9M)
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$3.1M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.97M |
| 3 |
Jane Street
New York
|
+$545K |
| 4 |
Barclays
London,
United Kingdom
|
+$27.1K |
| 5 |
U
UBS
Zurich,
Switzerland
|
+$10.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$14.7M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$2.02M |
| 3 |
HSBC Holdings
London,
United Kingdom
|
-$1.47M |
| 4 |
MCM
Moon Capital Management
New York
|
-$941K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$372K |
EVGN Hedge Fund Activity: Q1 2014 in Review
18 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q1 2014, worth a combined $79.8M — down 17% from $95.7M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new EVGN positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 9 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $3.1M. The largest seller was Goldman Sachs, cutting an estimated $14.7M.
- 18 institutional investors held Evogene (EVGN) as of Q1 2014, up from 17 in Q4 2013.
- Funds reported $79.8M of Evogene stock for Q1 2014, down 17% quarter-over-quarter.
- 3 funds opened new Evogene positions in Q1 2014 and 2 closed out, a net change of +1 holder.
- The largest Evogene buyer in Q1 2014 was JP Morgan Chase, an estimated $3.1M added.
- The largest Evogene seller in Q1 2014 was Goldman Sachs, an estimated $14.7M sold.
Based on aggregated 13F filings for Q1 2014.